ClinicalTrials.gg
RecruitingNCT07036796Updated Jul 21, 2026

Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy

A Phase 2 interventional study of Melatonin in Diabetic Peripheral Neuropathy, Diabetic Neuropathy and Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Ain Shams University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Diabetic Neuropathies with a site in Egypt — 9 open to participants now, 9 under way, none of them phase 3. Diabetic Neuropathies · Egypt.

Planned enrollment
8th of 22
60 · median 60
Started
2025
with 4 others
Phase 2
3 of 31
1 open now
Registered
26th of 31
by date
Lead sponsor
3 of 31
Ain Shams University

Among the 31 studies in Diabetic Neuropathies with a site in Egypt, this one is the 8th largest by planned enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 2, and was the 26th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

9 of the 31 studies in Diabetic Neuropathies with a site in Egypt are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Diabetic Neuropathies with a site in Egypt, or all of them as a file.
02

Study summary

The aim of the current study is to measure the effect of melatonin as adjunct therapy on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with diabetic peripheral neuropathy.

Read the detailed description

Diabetic neuropathy is a microvascular complication affecting 50% of patients throughout their lifetime. It leads to various complications including foot ulcerations and lower limb amputations, thus impairs the patient's quality of life. Distal symmetrical polyneuropathy is the most common subtype. Symptoms include tingling, burning and electrical pain associated with nocturnal exacerbation. Almost 50% of patients are asymptomatic thus diagnosis must include assessment of signs.

Pathophysiologic mechanism behind hyperglycemia induced nerve damage include the activation of various pathways including polyol and advanced glycation end product (AGE), which produces reactive oxygen species. Molecular studies have revealed the involvement of certain transcriptional regulators such as Nrf2-Keap1 and NfKb inflammatory cascade.

Nuclear erythroid growth factor-2 (Nrf2) functions primarily as a defense mechanism in cellular oxidative stress, producing anti-oxidant enzymes as glutathione reductase (GSH) and superoxide dismutase (SOD). However, in long term hyperglycemia, downregulation of nrf2 takes place, leading to accumulation of reactive oxygen species (ROS), which in turn activates nfkb inflammatory pathway and produces various cytokines such as tumor necrosis factor-alpha (Tnf-alpha), interleukin-1 (IL-1) and interleukin-6 (IL-6). Tumor-necrosis factor is known to be highly associated with nerve damage.

Drugs that target disease pathophysiology are currently unavailable, instead DPN management mainly depends on lifestyle modification through weight loss, blood pressure, blood glucose, lipid profile management along with symptomatic care. Yet these fail to stop disease progression.

Melatonin is known to possess anti-oxidant and anti-inflammatory properties through upregulating nrf2. It's hypothesized that adding it to standard therapy shall activate nrf2, and downregulate nfkb pathway and inflammatory cytokines, improving disease progression and patient's quality of life.

The aim of the current study is to measure the effect of melatonin on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with DPN.

All patients will be assessed for the following data at baseline:

  1. Age, gender, diabetes duration, diabetic neuropathy duration.
  2. HbA1c, liver functions, kidney functions and lipid profile.

Lab assessment will be done at both baseline and at the end of the trial to assess the effect of melatonin on the following:

  1. Nuclear erythroid related factor-2 (NRf2) (an oxidative marker)
  2. Tumor necrosis factor-alpha (an inflammatory marker)

Assessment of clinical outcomes will be done as well, at both baseline and endpoint using the following:

  1. Toronto clinical scoring system (TCSS)
  2. Michigan neuropathy screening instrument questionnaire (MNSIQ) Samples used to assess oxidative and inflammatory markers will be stored at -80 degrees to be analyzed later at the end of the study using ELISA kits.
03

Conditions studied

  • Diabetic Peripheral Neuropathy
  • Diabetic Neuropathy
  • Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients

Browse trials for

Keywords

  • Diabetic peripheral neuropathy
  • Diabetic neuropathies
  • Diabetic neuropathy in type 2 diabetes
  • Melatonin
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 40-75 years diagnosed with type 2 DM.
  2. Diabetes duration at least 1 year.
  3. Patients diagnosed with diabetic peripheral neuropathy.
  4. Stable antidiabetic medication for at least 1 month before enrollment and during the trial

Exclusion criteria

Exclusion Criteria:

  1. Patients with disorders (such as lupus and rheumatoid arthritis), thyroid diseases, peripheral arterial disease and cancer patients.
  2. Patients with severe kidney or liver dysfunction.
  3. Patients diagnosed with neurodegenerative diseases.
  4. Active infection.
  5. Use of medications or supplements known to cause or treat peripheral neuropathy.
  6. Alcohol consumption or substance abuse.
  7. Patients consuming any antioxidant supplements or anti-inflammatory medicines during or 3 months before enrollment.
  8. Pregnancy or lactation or expecting to get pregnant during the study.
  9. Allergy to melatonin.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Group 1: Melatonin group

    Group 1: Melatonin group (n=30) Patients will receive 10 mg (2 5mg Capsules) 1 hour before bedtime for 12 weeks, in addition to the standard therapy.

    Drug: Melatonin

  • No intervention
    Group 2: control group

    Group 2: No intervention, (n=30) patients will receive only standard therapy for 12 weeks

Interventions

  • Melatonin (N-acetyl-5-methoxytryptamine), also called the hormone of darkness, secreted primarily by the pineal gland. Possesses antioxidant, anti-inflammatory, anti-diabetic and neuroprotective effects. All of which could be explained by its activation of Nrf2 signaling pathway. Melatonin administration has shown to improve motor nerve conduction velocity and nerve blood flow, reduce the levels of pro-inflammatory cytokines, reinforce antioxidant defense, and decrease DNA fragmentation through upregulating nrf2 pathway, when tested in mice with diabetic peripheral neuropathy. Moreover, early treatment with melatonin has shown to prevent developing diabetic neuropathy in streptozotocin induced diabetic mice.

06

What researchers measure

Primary outcomes

  1. Concentration of human nuclear factor erythroid 2-related factor (Nrf2)

    Oxidative stress marker

    Time frame: Change from baseline human Nuclear factor erythroid 2-related factor at 3 months.

Secondary outcomes

  1. Concentration of Tumor necrosis factor alpha

    Inflammatory marker

    Time frame: Change from baseline Tumor necrosis factor alpha at 3 months

  2. Michigan neuropathy screening instrument questionnaire (MNSI-Q)

    A questionnaire of 15 yes or no questions, a score of 7 or more means more neuropathic symptoms

    Time frame: At baseline and after 3 months

  3. Toronto clinical scoring system (TCSS)

    A scoring system used to assess symptoms, reflexes and signs, as score increases indicates more neuropathy.

    Time frame: At baseline and after 3 months

  4. Diabetic neuropathy score (DNS)

    A score used to assess the major symptoms of DPN.

    Time frame: At baseline and after 3 months

  5. D-39 questionnaire

    A questionnaire used to test the effect of diabetes on patient's quality of life.

    Time frame: At baseline and after 3 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

Of 25 phase 2 interventional studies under Diabetic Neuropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 35. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jun 25, 2025
StartActual
Jul 4, 2025
Primary completionEst.
Jul 4, 2027
CompletionEst.
Jul 4, 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07036796
Responsible party
manar magdy (Demonstrator at Ain shams university, Ain Shams University) — Principal investigator
First posted
Jun 25, 2025
Start date
Jul 4, 2025
Primary completion
Jul 4, 2027 (estimated)
Completion
Jul 4, 2027 (estimated)
Last update
Jul 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melatonin

Start the discussion